The Pearson Lab integrates clinical expertise, mathematical modeling, high dimensional statistics, and basic tumor biology methods to investigate and propose new treatments for head and neck cancer.
University of Michigan
Ann Arbor, MI
Fellowship - Hematology/Oncology
2016
University of Michigan
Ann Arbor, MI
Postdoctoral Fellowship - Nor Lab (2013-2017)
2016
University of Michigan
Ann Arbor, MI
Residency - Internal Medicine
2012
University of Rochester
Rochester, NY
MD - Medicine
2010
University of Rochester
Rochester, NY
PhD - Statistics
2009
Cornell University
Ithaca, NY
BS - Biometry and Statistics
2002
Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning.
Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning. EBioMedicine. 2024 Aug 27; 107:105276.
PMID: 39197222
Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review.
Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review. Expert Rev Hematol. 2024 Aug 13; 1-9.
PMID: 39114884
Artificial Intelligence Applications in Oral Cancer and Oral Dysplasia.
Artificial Intelligence Applications in Oral Cancer and Oral Dysplasia. Tissue Eng Part A. 2024 Aug 07.
PMID: 39041628
Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer.
Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer. Cell Rep. 2024 Aug 27; 43(8):114551.
PMID: 39067022
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
PMID: 38842838
Evaluation of large language models as a diagnostic aid for complex medical cases.
Evaluation of large language models as a diagnostic aid for complex medical cases. Front Med (Lausanne). 2024; 11:1380148.
PMID: 38966538
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence.
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence. NPJ Breast Cancer. 2024 Jun 15; 10(1):46.
PMID: 38879577
Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma.
Artificial intelligence-based epigenomic, transcriptomic and histologic signatures of tobacco use in oral squamous cell carcinoma. NPJ Precis Oncol. 2024 Jun 08; 8(1):130.
PMID: 38851780
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. Res Sq. 2024 Jun 04.
PMID: 38883758
Quantum computing for oncology.
Quantum computing for oncology. Nat Cancer. 2024 Jun; 5(6):811-816.
PMID: 38760645
Mark Roth Award
University of Michigan
2015
Chief Fellow in Hematology/Oncology
University of Michigan
2014 - 2015